Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial

NCT07261709 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

236

Enrollment

OTHER

Sponsor class

Conditions

Refractory Metastatic Colorectal Cancer

Interventions

DRUG: Trifluridine/tipiracil plus fruquintinib
DRUG: trifluridine/tipiracil plus bevacizumab

Sponsor

Sun Yat-sen University